Abstract
Introduction
Stereotactic irradiation can be successfully used to limit or stop the growth ofbenign neoplasms ofthe skull base. Newer, low-dose protocols have decreased associated cranial nerve injuries, making stereotactic irradiation a useful alternative to microsurgical tumor excision in selected patients. In the posterior fossa, stereotactic irradiation is primarily used for the treatment of vestibular schwannomas or meningiomas using dosimetry designed to avoid cranial nerve morbidity, particularly to the facial nerve, while providing adequate dosing to control tumor growth.
Only one other report exists describing stereotactic irradiation specifically for the treatment of a facial schwannorna.' Facial nerve neoplasms are not typically selected for treatment with this modality because of the concern that direct irradiation to the facial nerve could cause significant and permanent facial nerve dysfunction. ' In this article ,we present the short-term outcomes of2 patients who underwent stereotactic irradiation to known facial nerve neoplasms.
Patients and methods
A retrospective review of charts from 1998 to 2005 identified 11 patients with the diagnosis of facial nerve neoplasms treated in our practice. Two of these patients underwent stereotactic irradiation for treatment oftheir tumors. Both patients have had at least 2 years offollowup, which has included post-treatment radiographic imaging to assess tumor response.
Results
Case1. Patient 1was a 53-year-old man initially treated at an outside institution for what was thought to be a right internal auditory mass and a separate temporal meningioma on the same side. These tumors were diagnosed via magnetic resonance imaging (MRI) 5 years prior to our first evaluation of this patient. The original MRI was ordered to evaluate the patient for Meniere disease diagnosed on the opposite ear; the tumors were an incidental finding. Interestingly, this patient had a history of sudden-onset, right -sided facialnerve paralysis with rapid spontaneous resolution prior to his initial workup. He was initially opposed to any therapy for these tumors; therefore, the referring physician elected to follow them with serial MRI. He was referred 5 years later to our practice because of progressive growth of the right temporal mass. The patient was asymptomatic on initial evaluation at our practice. His Meniere disease had caused vertigo spells and hearing fluctuation typical of this disorder in the past, but it was not active for several years prior to our evaluation. His cranial nerve examination was normal, with normal bilateral facialnerve function.Audiometrydemonstrated a speech-reception threshold (SRT) of 15 dB and a speech-discrimination score (SDS) of 96% on the right (tumor side), with an SRT of 55 dB and SDS of 80% on the left. His original MRI scans 5 years earlier had revealed the right-sided temporal and internal auditory canal lesions, which were 7 mm and 10 mm, respectively, in maximum dimension. Sequential MRIs were performed three times prior to our evaluation, each demonstrating slow but progressive growth of the temporal tumor. The MRI just prior to our evaluation revealed the temporal mass to be 1.8 ern in maximum diameter, with no change in the size of the internal auditory canal mass over 5 years (figure 1).
The patient was extensively counseled regarding his treatment options, which included continued observation, stereotactic irradiation, and surgical excision. He elected to undergo tumor removal via a middle fossa approach. The goal was removal of the growing temporal mass with internal auditory canal decompression for the nongrowing internal auditory canal mass, without excision, given that this was his significantly better hearing ear.
A middle fossa craniotomy was performed, and the temporal mass was easily identified during dural elevation. This mass was firmly attached to the geniculate fossa and was separate from the dura. This prompted suspicion that the mass was, in fact, part ofa facial nerve tumor and not a separate meningioma. The mass was confirmed as a facialnerve schwannoma by neural probe stimulation. The case was electively terminated without tumor excision so that we could properly discuss this specific pathology with the patient.
Afterseeking outside opinions at two other institutions, the patient elected to have his facial nerve schwannoma treated by stereotactic irradiation despite our expressed opinion to him that irradiation could deteriorate his hearing on the treated side . He underwent fractionated radiation treatment of the tumor with 5 fractions of500 cGy per fraction once per day for 5 days, delivering a total of 2,500 cGy.
The patient has been followed for 3 years since radio- Case 2. Patient 2 was a 51-year-old man who was sent to our practice for left-sided hearing loss and acuteonset facial nerve paralysis. On initial evaluation, he had House-Brackmann grade VINI .left-sided facial nerve paralysis . Audiometry revealed an asymmetric sensorineural hearing loss with an SRT of 15 dB and an SDS of 100% in the right ear, and an SRT of 20 dB and SDS of 100% in the left (affected) ear. MRI revealed an enhancing 4 mm x 2 mm left internal auditory canal lesion ( figure 2) . Additionally, the geniculate ganglion and tympanic segment of the facial nerve also had greater contrast uptake than the opposite side,indicating tumor in these sections. Electroneurography showed a 98% weakness compared to the other side, and electromyography revealed fibrillation potentials in the oculi, frontalis, and oris muscles.
After comprehensive consultation regarding treatment options, the patient elected to proceed with stereotactic irradiation. He was counseled regarding concerns that nerve grafting would likely be necessary to restore lost facial nerve function, but he insisted that he did not want to undergo surgical treatment that would take him www.entj ourna l.com • 575 away from his work. He therefore underwent treatm ent with singledose stereotactic irradiation delivered by a linear accelerator with 1,200 cGy prescribed to the 90% isodose line. This patient has been followed for 24 months since treatment. His last MRI showed no tumor grow th . Intere stingly, h is facial nerve fun ction significantly improved 3 months after treatment , and on his last follow-up, his facial nerve function was at House -Brackmann grade III/VI. Audio metry has demonstrated a significant decrease in auditory thresholds, however, with his pure tone average decreasing to 46 dB and his SDS decreasing to 80% in the left ear at 2 years post-treatment.
Discussion
Facial schwannomas are veryslow growing and are often diagnosed in patients with normal facial ner ve function. In addition,facialschwannomas are often integrated into the axons of the nerve , making preservation of the facial nerve difficult during surg ical excision. Many authors therefore advocate a perio d of observa tion, with surgical intervention if facial nerve func tion is compromised by the tumor or if the tumor demonstrates significant growth .' Other aut hors suggest tha t excision sho uld be performed while th e tumor is still very small so th at th e pro bability of preserving the facial nerve is increased ." Regardless of m anagement ph ilosop hy, th ese tu mors remain a therapeutic challenge because of th e risk of facial nerve injur y-either from progressive growth of the tumor or from surgica l trauma.
The authors are on ly aware of one other case report of stereotactic irradiation used for the treatment of facial schwannoma. I Apprehension regarding the use of stereotactic irradiation for these tumors is fueled by legitimate concerns th at radiation can induce microvasculitis and axonal degeneration in target neural tissue.' Stereotactic irradiation is an accepted treatment for vestibular schwannomas, however, with facial ner ve and hearing results comparable to those attai ned with surgery,"Lower-dose pro tocolsand improved dosimetry planning continue to lower crania l nerve complications. 7 Most protocols for vestibular schwannomas attempt to mini mize ra diation exposure to the facial nerve in 576 • www.entjournal.com an effort to decrease the risk of para lysis, altho ugh in reality this is difficult given the close approximation of the facial nerve to these tumors.
Stereotactic irra diation can be delivered either in a single fractio n or in multiple fractions. Both technical and radiobiologic rationales exist for these approaches. Technically,linear-accelerator-based radiotherapy systems allow for single-fraction or fractionated treatment. The Gamma knife is limited to single-fraction therapy. From a radiobiologic standpoint , there is established value to fractio nation in limiting damage to normal structures by allowing for repai r of sublethal damage to normal tissues that occurs between fract ions. In order to deliver a radiobiologically equivalent dose to th e tumor, higher total doses of radiation are delivered with a fractiona ted approach (i.e., 2,500 vs. 1,200 cGy in this review). Both techniqu es have an established indication for the treatmen t of acoustic neuromas.
The mainstay of facial nerve schwannoma treat ment at Pittsburgh Ear Associates continues to be a period of observation followed by surgical tumor excision and potential facial nerve grafting if the tumor is growing or if facial nerve function has clinically deteriorated. The 2 unusual cases presented in this report, in which the patients specifically chose to undergo radiotherapy, entertain the question ofwhether radiotherapy for facial nerve schwannomas may be a legitim ate the rapeutic alternative to this approach. In both cases, the patien ts were offered surgery or observation, but for various reasons they elected to undergo stereotactic irr adiation. Both tumors appear to be controlled over th e first few years, but no conclusive statement can be made abo ut long-term control. Weassume that contro l rates for these facial nerve schwannomas would be simil ar to those for vestibular schw annomas, but this assumption is not suppor ted by th e liter ature or this study.
Th e critical observation in thi s series is tha t facial nerve fun ction has been stable or imp roved in our 2 patients following radiotherapy.Despite con cern s about intentional and direct irradiation to the facial axons, Patient 1 continues to have House-Brackmann grade I function more th an 3 years po st-treatment,and Patient 2 improved substantially from a House-Brackmann grade VI to a grade III in a m atter of 12 months after surg ery. Improvements in dosimetry planning, lower radiation do ses (12 Gy in Patient 2), and fractionation (Patient 1), have likely decreased neural m orbidity substantially, contributing to these results. Another important obse rvation is th at both patients have significant hearing loss in the tr eated ear, a likely effect of irradiation.
Although stereotactic irradi ation may be a valuable alternative to surgical intervention for facial nerve schwannomas, the authors still recomme nd a per iod of ob servation with sur gical int ervention for demonstr ated tumor growth or progressive facial nerve function deterioratio n, for th e following reasons:
1. Long-t erm stereotactic irradiation tumorcontrol ra tes are not known.
2. Lon g-term facial nerve function results are not known.
3.Surgic al intervention may be more difficult after irr adi ation, and graft-take rates m ay be affected."
4. There is concern about m align an t tr an sformation, especially in young pati ents.v'?
Radi otherapy for facial schwa nno mas remains an excellent alternative for older patient s and for pati ents with medical contraindications for surg ery.These indications may broaden once lon ger-term follow-up data become available. Therefore, thi s approach war rants further investigation.
